“…This is in agreement with numerous studies showing that gain-of-function mutations in β-catenin signaling and loss of α-catenin regulation are prevalent in cancer (Aaltomaa et al, 1999;Anttila et al, 1998;Clevers and Nusse, 2012;Gofuku et al, 1999;Lifschitz-Mercer et al, 2001;Matsui et al, 1994;Nakopoulou et al, 2002;Polakis, 2000;Richmond et al, 1997;Rimm et al, 1995;Shiozaki et al, 1994;Silvis et al, 2011;Tanaka et al, 2003;van Oort et al, 2007;Yang et al, 2006). This additional level of regulation by α-catenin may help explain why WNT stimulation has been reported to decrease the sensitivity of cells to DNA damage despite increased nuclear β-catenin levels (Chandra et al, 2015;Chen et al, 2007;Jun et al, 2016;Woodward et al, 2007), and why different experimental systems have had confounding results (Chevillard-Briet et al, 2014;Orford et al, 1999;Tao et al, 2015;Watson et al, 2010). Intriguingly, p53 is able to regulate WNT ligand production in a cell type-dependent manner (Lee et al, 2010) as well as β-catenin levels (Kim et al, 2011; Sadot Our results suggest that the effect of WNT stimulation on the DNA damage response may depend on the levels of nuclear α-catenin, as well as those of β-catenin and other proteins recruited to this complex.…”